Physician profile
Edison Goncalves
NPI 1457309593
$141,917.80
in general payments reported to CMS, 2019-2025
33 companies · $451 in 2025
The $451 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $19K · 2021: $7,431 · 2022: $26K · 2023: $10K · 2024: $7,118 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,043 · Education: $73.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,752.25 |
| Food and Beverage | $2,042.53 |
| Education | $73.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $134,123.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $2,844.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $749.88 | 2019-2021 | |
| Corcept Therapeutics | $559.73 | 2019-2025 | Korlym |
| Dexcom, INC. | $503.66 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $375.35 | 2019-2025 | |
| Abbott Laboratories | $326.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $276.44 | 2021-2025 | |
| Abbvie INC. | $265.65 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $167.44 | 2019-2020 | |
| Lilly USA, LLC | $158.00 | 2019-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $131.61 | 2019 | |
| Ibsa Pharma INC. | $130.64 | 2019-2025 | Tirosint, Licart, Flector |
| Mannkind Corporation | $121.92 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $119.11 | 2019-2025 | Repatha |
| Tandem Diabetes Care, INC. | $117.32 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Scientific Affairs, LLC | $110.08 | 2019 | |
| Beta Bionics, INC. | $105.76 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic Minimed, INC. | $82.13 | 2019 | |
| Horizon Therapeutics Plc | $64.43 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $61.61 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $60.49 | 2021-2025 | Minimed 780g |
| Antares Pharma, INC. | $39.75 | 2019-2022 | |
| Shire North American Group INC | $39.53 | 2019 | |
| Radius Health, INC. | $33.49 | 2019 | |
| Amarin Pharma, INC. | $30.73 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.33 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $23.61 | 2022 | |
| Esperion Therapeutics, INC. | $18.50 | 2021 | |
| Averitas Pharma INC. | $18.44 | 2025 | Qutenza |
| Amneal Pharmaceuticals LLC | $14.01 | 2021 | |
| Eisai INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edison Goncalves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.